A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/05 (2006.01) A61K 31/44 (2006.01) A61K 38/55 (2006.01)
Patent
CA 2234899
FIXED-DOSE ASSOCIATION OF AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND OF A CALCIUM CHANNEL ANTAGONIST, METHOD FOR PREPARATION AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR ILLNESSES Comprises a dose of (a) enalapril or a pharmaceutically acceptable salt thereof and another dose of (b) nitrendipine or a pharmaceutically acceptable salt thereof and in that it is administered in single-dose gallenic form. The method comprises: (a) dissolving enalapril maleate in water with an inorganic salt; (b) mixing the micronized nitrendipine with a fraction of she disintegrating excipients, the wetting agent, the fragmentary diluting agent, the agglutinating agent, and the plastic diluting agent, previously sieved; (c) granulating- the products homogenized in section (b) with the solution obtained in section (a); (d) drying the granulated mass; (e) incorporating the lubricating agent, and the remaining fraction of the disintegrating excipients and homogenizing the calibrated granulate; (f) compressing the granulate. Use of said association for the manufacture of a medicament for the treatment of illnesses of the cardiovascular system.
Canovas Soler Pedro
Delgadillo Duarte Joaquin
Micheto Escude Luis Manuel
Ferrer Internacional S.a.
Robic
Vita-Invest S.a.
LandOfFree
Fixed-dose association of an angiotensin-converting enzyme... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fixed-dose association of an angiotensin-converting enzyme..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fixed-dose association of an angiotensin-converting enzyme... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1369430